City

Tianjin (1)

Condition

MF (2)

AML (1)

CRPC (1)

ESCC (1)

Malignant Tumor (1)

Myelofibrosis (1)

NSCLC (1)

Ovarian Carcinoma (1)

SCLC (1)

Overall Status

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

n/a (1)

phase 1/phase 2 (1)

Sponsor

Jacobio Pharmaceuticals Co., Ltd. (1)

Marina Kremyanskaya (1)

Collaborator

Incyte Corporation (1)

Intervention

busulfan (1)

filgrastim (1)

jab-8263 (1)

ruxolitinib / inc 424 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

mf

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

NSCLC, SCLC, CRPC Trial in Tianjin (JAB-8263)

Recruiting

NSCLC
+7 more

JAB-8263

Tianjin, Tianjin, China

Tianjin

Mar 11, 2022

Myelofibrosis, MF Trial (RUXOLITINIB / INC 424, Filgrastim, Busulfan)

Withdrawn

Myelofibrosis
MF

RUXOLITINIB / INC 424
+2 more

(no location specified)

Aug 11, 2016